Goetzinger Catherine, Alleaume Caroline, Schritz Anna, Vrijens Bernard, Préau Marie, Fagherazzi Guy, Huiart Laetitia
Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.
University of Luxembourg, Faculty of Science, Technology and Medicine, Esch-sur-Alzette, Luxembourg.
Front Pharmacol. 2022 Sep 27;13:889695. doi: 10.3389/fphar.2022.889695. eCollection 2022.
Up to 50% of breast cancer (BC) survivors discontinue their adjuvant endocrine therapy (AET) before the recommended 5 years, raising the issue of medication non-adherence. eHealth technologies have the potential to support patients to enhance their medication adherence and may offer an effective way to complement the healthcare. In order for eHealth technologies to be successfully implemented into the healthcare system, end-users need to be willing and accepting to use these eHealth technologies. This study aims to evaluate the current usability of eHealth technologiesin and to identify differences in BC SURVIVORS BC survivors accepting a medication adherence enhancing eHealth technology to support their AET to BC survivors that do not accept such a medication adherence enhancing eHealth technology. This study was conducted in 2020 including volunteering BC survivors belonging to the Seintinelles Association. Eligible participants were women, diagnosed with BC within the last 10 years, and been exposed to, an AET. Univariable and multivariable logistic regression analyses were performed to investigate medication adherence enhancing eHealth technology acceptance profiles among BC survivors. The dependent variable was defined as acceptance of an electronic pillbox connected to a smartphone application (hereafter: medication adherence enhancing eHealth technology). Overall, 23% of the participants already use a connected device or health application on a regular basis. The mean age of the participants was 52.7 (SD 10.4) years. In total, 67% of 1268 BC survivors who participated in the survey declared that they would accept a medication adherence enhancing eHealth technology to improve their AET. BC survivors accepting a medication adherence enhancing eHealth technology for their AET, are younger (OR = 0.97, 95% CI [0.95; 0.98]), do take medication for other diseases (OR = 0.31, 95% CI [0.13; 0.68]), already use a medication adherence enhancing eHealth technology or technique (OR = 1.74, 95% CI [1.06; 2.94]) and are willing to possess or currently possess one or more connected devices or health applications (OR = 2.89, 95% CI [2.01; 4.19]). Understanding acceptance profiles of BC survivors is fundamental for conceiving an effective eHealth technology enhancing AET among BC survivors. Hence, such profiling will foster the development of personalized medication adherence enhancing eHealth technology.
高达50%的乳腺癌(BC)幸存者在推荐的5年疗程之前就停止了辅助内分泌治疗(AET),这引发了药物治疗依从性的问题。电子健康技术有潜力支持患者提高药物治疗依从性,并可能提供一种有效的方式来补充医疗保健。为了使电子健康技术成功应用于医疗保健系统,最终用户需要愿意并接受使用这些电子健康技术。本研究旨在评估电子健康技术目前的可用性,并确定接受增强药物治疗依从性的电子健康技术以支持其AET的BC幸存者与不接受此类增强药物治疗依从性的电子健康技术的BC幸存者之间的差异。本研究于2020年进行,纳入了属于Seintinelles协会的自愿参与的BC幸存者。符合条件的参与者为女性,在过去10年内被诊断为BC,并接受过AET。进行单变量和多变量逻辑回归分析,以研究BC幸存者中增强药物治疗依从性的电子健康技术接受情况。因变量被定义为接受与智能手机应用程序连接的电子药盒(以下简称:增强药物治疗依从性的电子健康技术)。总体而言,23%的参与者已经经常使用连接设备或健康应用程序。参与者的平均年龄为52.7(标准差10.4)岁。在参与调查的1268名BC幸存者中,共有67%的人表示他们会接受增强药物治疗依从性的电子健康技术来改善他们的AET。接受增强药物治疗依从性的电子健康技术以进行AET的BC幸存者更年轻(比值比=0.97,95%置信区间[0.95;0.98]),确实因其他疾病而服药(比值比=0.31,95%置信区间[0.13;0.68]),已经使用增强药物治疗依从性的电子健康技术或方法(比值比=1.74,95%置信区间[1.06;2.94]),并且愿意拥有或目前拥有一个或多个连接设备或健康应用程序(比值比=2.89,95%置信区间[2.01;4.19])。了解BC幸存者的接受情况对于构思一种有效的增强BC幸存者AET的电子健康技术至关重要。因此,这种情况分析将促进个性化的增强药物治疗依从性的电子健康技术的发展。